Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based treatments like DT120 (LSD) and DT402 (MDMA) for psychiatric disorders. As of November 2, 2026, the company had 136,899,935 common shares outstanding and is currently conducting Phase 3 clinical programs for generalized anxiety disorder and major depressive disorder.
Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.
Term
Q3 2026
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”
Rob Barrow, Chief Executive Officer
“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”